MAPT and Alzheimer disease: Translationally, positron emission tomography (PET) imaging using tau-specific tracers [e.g., (∧18F)AV-1451, (∧18F)MK-6240] has enabled the in vivo assessment of tau deposition in patients with late-life depression and early-stage AD, providing a bridge between preclinical findings and clinical relevance.